Humme D, Beyer M, Röwert-Huber H-J, Sterry W, Philipp S
Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin.
Hautarzt. 2013 Mar;64(3):190-4. doi: 10.1007/s00105-012-2526-5.
The development of malignancies during therapy with biologics has been discussed controversially. A patient with extensive pityriasis rubra pilaris failed to respond to standard therapeutic approaches. While receiving immunomodulatory therapy, lastly with ustekinumab, the patient developed a CD30(+) anaplastic large cell lymphoma.
生物制剂治疗期间恶性肿瘤的发生一直存在争议。一名患有广泛性毛发红糠疹的患者对标准治疗方法无反应。在接受免疫调节治疗期间,最后使用乌司奴单抗时,该患者发生了CD30(+)间变性大细胞淋巴瘤。